BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17260012)

  • 1. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
    Jönsson G; Dahl C; Staaf J; Sandberg T; Bendahl PO; Ringnér M; Guldberg P; Borg A
    Oncogene; 2007 Jul; 26(32):4738-48. PubMed ID: 17260012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profiling.
    Cifola I; Pietrelli A; Consolandi C; Severgnini M; Mangano E; Russo V; De Bellis G; Battaglia C
    PLoS One; 2013; 8(5):e63597. PubMed ID: 23704925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic characterisation of acral melanoma cell lines.
    Furney SJ; Turajlic S; Fenwick K; Lambros MB; MacKay A; Ricken G; Mitsopoulos C; Kozarewa I; Hakas J; Zvelebil M; Lord CJ; Ashworth A; Reis-Filho JS; Herlyn M; Murata H; Marais R
    Pigment Cell Melanoma Res; 2012 Jul; 25(4):488-92. PubMed ID: 22578220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis.
    Furney SJ; Turajlic S; Stamp G; Thomas JM; Hayes A; Strauss D; Gavrielides M; Xing W; Gore M; Larkin J; Marais R
    Pigment Cell Melanoma Res; 2014 Sep; 27(5):835-8. PubMed ID: 24913711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors.
    Heidenblad M; Lindgren D; Jonson T; Liedberg F; Veerla S; Chebil G; Gudjonsson S; Borg A; Månsson W; Höglund M
    BMC Med Genomics; 2008 Jan; 1():3. PubMed ID: 18237450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tracing cancer evolution and heterogeneity using Hi-C.
    Erdmann-Pham DD; Batra SS; Turkalo TK; Durbin J; Blanchette M; Yeh I; Shain H; Bastian BC; Song YS; Rokhsar DS; Hockemeyer D
    Nat Commun; 2023 Nov; 14(1):7111. PubMed ID: 37932252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial.
    Arnaud-Coffin P; Brahmi M; Vanacker H; Eberst L; Tredan O; Attignon V; Pissaloux D; Sohier E; Cassier P; Garin G; Pérol D; Blay JY; Dufresne A
    Transl Oncol; 2020 Dec; 13(12):100870. PubMed ID: 32950930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptome-Based Treatment for Melanoma With Brain Metastasis: A Case Report.
    Ayass MA; Melendez K; Griko N; Zhang J; Abi-Mosleh L
    Cureus; 2024 Mar; 16(3):e56494. PubMed ID: 38638737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Regulations upon Hydrogel-Mediated Drug Delivery Systems in Skin Cancers-An Overview.
    Mathiyalagan R; Kariyarath Valappil A; Yang DC; Kang SC; Thambi T
    Gels; 2022 Sep; 8(9):. PubMed ID: 36135270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis.
    Farshidfar F; Rhrissorrakrai K; Levovitz C; Peng C; Knight J; Bacchiocchi A; Su J; Yin M; Sznol M; Ariyan S; Clune J; Olino K; Parida L; Nikolaus J; Zhang M; Zhao S; Wang Y; Huang G; Wan M; Li X; Cao J; Yan Q; Chen X; Newman AM; Halaban R
    Nat Commun; 2022 Feb; 13(1):898. PubMed ID: 35197475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dosimetric enhancement of GRID profiles using an external collimator in pencil beam scanning proton therapy.
    Smith BR; Nelson NP; Geoghegan TJ; Patwardhan KA; Hill PM; Yu J; Gutiérrez AN; Allen BG; Hyer DE
    Med Phys; 2022 Apr; 49(4):2684-2698. PubMed ID: 35120278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal pathways of melanoma and targeted therapy.
    Guo W; Wang H; Li C
    Signal Transduct Target Ther; 2021 Dec; 6(1):424. PubMed ID: 34924562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of robust reference genes for studies of gene expression in FFPE melanoma samples and melanoma cell lines.
    Christensen JN; Schmidt H; Steiniche T; Madsen M
    Melanoma Res; 2020 Feb; 30(1):26-38. PubMed ID: 31567589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Resolution Copy Number Patterns From Clinically Relevant FFPE Material.
    Filia A; Droop A; Harland M; Thygesen H; Randerson-Moor J; Snowden H; Taylor C; Diaz JMS; Pozniak J; Nsengimana J; Laye J; Newton-Bishop JA; Bishop DT
    Sci Rep; 2019 Jun; 9(1):8908. PubMed ID: 31222134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.
    Cirenajwis H; Lauss M; Ekedahl H; Törngren T; Kvist A; Saal LH; Olsson H; Staaf J; Carneiro A; Ingvar C; Harbst K; Hayward NK; Jönsson G
    Mol Oncol; 2017 Apr; 11(4):438-451. PubMed ID: 28267273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TBX2 represses PTEN in rhabdomyosarcoma and skeletal muscle.
    Zhu B; Zhang M; Williams EM; Keller C; Mansoor A; Davie JK
    Oncogene; 2016 Aug; 35(32):4212-24. PubMed ID: 26686089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
    Wilson MA; Zhao F; Khare S; Roszik J; Woodman SE; D'Andrea K; Wubbenhorst B; Rimm DL; Kirkwood JM; Kluger HM; Schuchter LM; Lee SJ; Flaherty KT; Nathanson KL
    Clin Cancer Res; 2016 Jan; 22(2):374-82. PubMed ID: 26307133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variations of BRAF mutant allele percentage in melanomas.
    Hélias-Rodzewicz Z; Funck-Brentano E; Baudoux L; Jung CK; Zimmermann U; Marin C; Clerici T; Le Gall C; Peschaud F; Taly V; Saiag P; Emile JF
    BMC Cancer; 2015 Jul; 15():497. PubMed ID: 26141748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.
    Lauss M; Haq R; Cirenajwis H; Phung B; Harbst K; Staaf J; Rosengren F; Holm K; Aine M; Jirström K; Borg Å; Busch C; Geisler J; Lønning PE; Ringnér M; Howlin J; Fisher DE; Jönsson G
    J Invest Dermatol; 2015 Jul; 135(7):1820-1828. PubMed ID: 25705847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-proliferative function of the TGF-β1 signaling pathway involves the repression of the oncogenic TBX2 by its homologue TBX3.
    Li J; Ballim D; Rodriguez M; Cui R; Goding CR; Teng H; Prince S
    J Biol Chem; 2014 Dec; 289(51):35633-43. PubMed ID: 25371204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.